Clinical Trial Update: A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nivolumab in combination with Bacillus Calmette-Guérin (BCG) versus BCG alone in high-risk non-muscle invasive bladder cancer was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urinary Bladder Neoplasms

Drugs mentioned

• Bacillus Calmette-Guérin (Bacillus Calmette-Guérin)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Urinary Bladder Neoplasms | Phase 3 | Status: TERMINATED | Results posted: 2025-09-16